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Are somatic mutations predictive of response to 
erythropoiesis stimulating agents in lower risk
myelodysplastic syndromes?
Erythropoiesis stimulating agents (ESA) are generally
first-line treatments of anemia in lower risk myelodys-
plastic syndrome (MDS), yielding response rates of 30 to
60%, median response duration of 20 to 24 months1,2 and
a possible survival improvement compared to RBC trans-
fusions alone.1-3 Main consensus prognostic factors of
better response to ESA include low or int-1 IPSS, low
RBC transfusion burden, and low serum EPO (sEPO).4
Other reported prognostic factors for response to ESA
include marrow multilineage dysplasia,  flow cytometry
scoring,5 ERK and STAT5 phosphorylation in erythrob-
lasts,6,7 and IPSS-R.8
Somatic mutations are found in up to 80% of MDS.
Many of them and/or their number have been correlated
with outcome irrespective of treatment,9 or after specific
treatments like allogeneic SCT10 or hypomethylating
agents.11 To our knowledge, however, the prognostic
value of somatic mutations in response to ESA has not
been assessed.  Here, we analyzed whether they predict-
ed results of ESA treatment in lower risk MDS, and added
prognostic value to conventional factors.
Seventy-nine lower risk MDS patients treated with
ESA by the French (GFM), Italian (FISM) and German (D-
MDS) MDS cooperative groups were included based on
the availability of all the following data: sEPO, serum fer-
ritin (SF) level, marrow slides for central review by cyto-
morphologists to evaluate dysplastic features homoge-
neously, bone marrow DNA, and written informed con-
sent for molecular analysis. To be included, patients
haematologica 2016; 101:e280
LETTERS TO THE EDITOR
Table 1. Variables related with ESA response, including variables with P<0.1 in univariate analysis, for the multivariate analysis.
Variables Total (n) Response  to Univariate analysis OR P Multivariate analysis,
ESA(%) (CI 95%) P
Sex
female 35 77.1
male 44 54.5 0.35 [0.13-0.95] 0.03 0.04
Age (y)
>75 33 69.7 0.43
<75 46 61 1.53 [0.58-4.04]
WHO







LOW 35 72 1.87 [0.72-4.87] 0.19
INT-1 42 57
IPSS-R
VERY LOW/LOW 51 73 3.08 [1.15-8.27] 0.02
INT 26 46 0.04
Bone marrow dysplasia
Dyserythropoiesis 67 58 0.2
Dysgranulopoiesis 49 60 0.36
Dysmegakaryopoiesis 53 65 0.36
Serum EPO
<100 IU/L 55 76 0.002 0.04
>100 IU/L 24 39 0.19 [0.07-0.57]
Serum ferritin
<400 ng/mL 37 73 0.28
>400 ng/mL 42 57
Transfusion dependence
yes 21 48 0.38 [0.13-1.05] 0.058 0.03
no 59 71
Number of mutations>2
yes 28 46 0.29 [0.11-0.78] 0.01
no 51 74 0.29
Karyotype
Normal 52 63 0.93 [0.33-2.66] 0.9
Abnormal 21 62
NA 6
OR: odds ratio.CI: confidence interval.
should have received high dose ESA, i.e., EPO (60,000
units/week) or darbepoetin (250 to 300 ug/week) for at
least 12 weeks, with or without G-CSF. Marrow dysplas-
tic features were reviewed blindly by a panel of cytomor-
phologists, applying 2008 WHO criteria.11 Ethical
approval was obtained by participating groups. 
Mutational analysis of the 37 most frequently mutated
genes in MDS (listed in Online Supplementary Table S2)
was performed on marrow cell DNA collected before
ESA treatment, using an Ion AmpliSeq platform (Life
Technologies, Carlsbad, USA).12-13 The variant allele fre-
quency (VAF) was calculated by dividing the number of
mutated reads by the total number of reads at the posi-
tion of each mutation. In patients harboring at least 2
mutations, clonal heterogeneity was evaluated by χ2 test
to determine if the VAF were significantly different.
When several mutations were present, mutations with
significantly higher VAF were considered as major, and
mutations with significantly lower VAF as minor. In the
absence of significantly different VAF, all identified muta-
tions were considered as major.
Erythroid response (HI-E) was defined using IWG 2006
criteria. Logistic regression analysis was used for multi-
variate analysis of HI-E. Overall survival (OS) from ESA
onset and response duration were calculated using the
Kaplan-Meier method. A Cox regression model was used
to test prognostic factors for response duration and OS. 
Of the patients, 26% were RBC transfusion dependent
(TD) (Online Supplementary Table S1). In total, 85% of
the patients had significant (>10%) dyserythropoiesis,
62% dysgranulopoiesis, and 67% dysmegakaryopoiesis.
IPSS was low (45%), int-1 (53%), and not assessable
(NA) (2%). IPSS-R was very low (6%), low (58%), inter-
mediate (33%), and NA (2%). HI-E was 64.5%, and
median response duration was 19 months, in agreement
with previous reports.1,2 RBC transfusion independence
(RBC-TI) was achieved in 47% of the TD patients. 
Sequencing results (Figure 1, Online Supplementary
Table S2) were interpretable for all genes in all samples.
We identified 159 mutations in the 79 patients, including
88 missense, 36 InDel, 28 stopgain, and 7 splicing muta-
tions. A total of 86% of the patients had at least one
mutation (median number of mutations 2, range 0-6). 
Mutations were found in more than 10% of the
patients for SF3B1 (40.5% of the  patients), TET2
(30.3%), ASXL1 (27.8%), DNMT3A (20.2%), RUNX1
(12.6%), STAG2 (11.4%), U2AF1 (10.1%) (Online
Supplementary Table S2), and involved splicing factors
(SF3B1, SRSF2, U2AF1, ZRSR2) (62% of the patients),
DNA methylation modifiers (TET2, IDH1, IDH2,
DNMT3A) (56%), chromatin modifiers (ASXL1, EZH2,
KDM6) (32%), transcription factors (RUNX1, TP53,
BCOR, PHF6) (16%), and signaling pathway genes
(NRAS, CBL, JAK2, PTPN11) (13%). 
VAF comparison between mutated genes in each
patient revealed 2 types of clonal patterns: 45 (57%)
patients had only one major clone with 1 to 5 mutations
(pattern 1), while 34 (43%) patients had a major clone
and minor subclone(s) (pattern 2) (Online Supplementary
Figure S1). Most mutations were found in major clones;
however, 2 of 3 EZH2, 3 of 4  NRAS,  and all 5 STAG2
mutations were represented only in minor subclones.  
In univariate analysis (Table 1), male sex (P=0.03),
sEPO level >100U/L (best discriminant threshold in this
study) (P=0.002), and intermediate IPSS-R (P=0.02) were
significantly correlated with worse HI-E; RBC-TD had
borderline significance (P=0.058); and Hb level, platelet
count, ANC, age, karyotype, and importance of dysplasia
(after central review) had no significant prognostic
impact. 
HI-E was 73% and 63% in patients with no mutation,
and at least one mutation, respectively (P=0.44). HI-E
was 74% in the 51 patients with ≤ 2 mutations versus
46% in the 28 patients with >2 mutations (P=0.01) (Table
1). The cut-off point of 3 mutations was chosen because
HI-E was 73%, 71%, 79%, 47%, and 38% in patients
haematologica 2016; 101:e281
LETTERS TO THE EDITOR
Figure 1. Barcode in the global cohort. Rows correspond to cytogenetics (normal vs. abnormal) or sequenced genes, and columns represent individual
patients. Color coding is based on the category of gene mutated. Karyotype white= normal/black= abnormal/grey=NA. Erythroid response IWG 2006 white=no/
grey= yes.
with 0, 1, 2, 3 and 4 mutations, respectively. All patients
with >2 mutations had multilineage dysplasia, compared
with 63% of the patients with ≤ 2 mutations (P=0.01).
HI-E was 57% and 65% in patients with mutational pat-
tern 1 (one major clone) and mutational pattern 2 (major
and minor  subclones), respectively (P=0.62).
Individual mutation of the most frequently mutated
genes (SF3B1, TET2, ASXL1, DNMT3A), mutation in a
particular gene category (DNA methylation, chromatin
modifier, splicing factor, transcription factors, signalling
pathways) or mutation of the following genes associated
with poor OS in MDS  (ASXL1, TP53, RUNX1) had no
significant impact on HI-E (Online Supplementary Table
S2). In particular, HI-E was 58% in the 32 patients with
SF3B1 mutation (31 of whom had received ESA without
G-CSF) versus 68% in patients without SF3B1 mutation
(P=0.4). 
In an adjusted logistic regression model, male sex,
sEPO level>100U/L, RBC-TD and IPSS-R, but not the
number of mutations or presence of mutations in a par-
ticular gene category, were significantly correlated with
HI-E (Table 1). 
Median response duration to ESA was 19 months
(range 3-134). Mutations (individual or by gene category),
their number, the mutational pattern (major or minor
subclones), multilineage (versus unilineage) dysplasia,
sEPO level, karyotype, IPSS-R, age, sex, and TD were not
significantly correlated with response duration (data not
shown). 
Median OS was 42.5 months. Individual gene muta-
tions, mutations in specific gene categories, and the
mutational pattern (major or minor subclones) had no
significant impact on OS. On the other hand, patients
with >2 mutations had a median survival of 32 months
vs. 92 months in patients with ≤ 2 mutations (P=0.04;
Online Supplementary Figure S2A). Increasing number of
mutations correlated with worse OS (P=0.01, Online
Supplementary Figure S2B). In multivariate analysis,
IPSS-R and >2 mutations significantly and independently
influenced OS (Table 2). 
In this first next generation sequencing study of lower
risk MDS patients treated by ESA, to our knowledge,
having >2 somatic mutations was associated with lower
HI-E. While previous studies have shown the prognostic
value of somatic mutations in MDS (irrespective of treat-
ment, or with hypomethylating agents or allogeneic
SCT),9,10 their predictive role in response to ESA has not
previously been studied. In the present series, the
response rate to ESA was relatively high (64.5%), proba-
bly due to the fact that all patients had lower risk MDS,
serum EPO level < 500 U/l, were generally not RBC TD,
and received high ESA dose (60,000 IU/week of EPO,
250- 300mg/week of darbepoietin). Frequent individual
mutations (SF3B1, TET2, ASXL1, DNMT3A), mutations
in particular gene categories and mutational patterns
(major subclones only or coexistence of major and minor
subclones) had no significant impact on response. In
addition, in multivariate analysis, prognostic factors of
HI-E were serum EPO level, RBC TD, and IPSS-R,8 whilst
number or type of mutation were not. Thus, although
future analysis of somatic mutations in larger patient
cohorts may lead to different conclusions, conventional
parameters, especially RBC-TD, sEPO level and IPSS-R,
currently appear sufficient to predict response to ESA
treatment in routine practice.
Whilst the number of mutations correlated with lower
HI-E in univariate analysis, it was not significantly asso-
ciated with response duration to ESA. Based on these
results from a relatively small cohort, systematic analysis
of the gene mutation profile may not be considered nec-
essary to predict response to ESA in lower risk MDS
patients. On the other hand, the mutational profile could
be useful to predict OS in lower risk MDS, as the pres-
ence of >2 mutations correlated with worse OS inde-
pendently of IPSS-R. Similarly, a poorer OS based on
mutation number was reported, though independently of
treatment, by Bejar et al. and Papaemmanuil et al.9,10,14
Furthermore, since lower risk IPSS patients with more
than 2 gene mutations treated with ESA possibly have
shorter OS, alternative treatments may be required in
these cases. Our results, however, warrant confirmation
on larger patient cohorts with precise treatment descrip-
tion.
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Table 2. Multivariate analysis for OS. Including variables with P<0.1
in univariate analysis.
OS
HR CI 95% P
Age>75 vs. <75 years 1.21 [0.54-2.73] 0.63
Sex (M vs. F) 0.83 [0.36-2.02] 0.67
Number of mutations (>2 vs. <=2) 2.53 [1-7.2] 0.05
IPSS-R
Intermediate/low 2.22 0.04
Low/very low 6.105 0.08
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